Researchers suggest that application of Nobel-prize-winning portfolio theory could provide objective funding allocations that would improve risk/reward trade-off in years of life lost.
The National Institutes of Health (NIH) is one of the largest investors in biomedical research—spending approximately $30 billion dollars annually—and must constantly evaluate how to spend those dollars in a way that adequately reflects multiple factors including disease burden.